A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis
Principal Investigator
Vincent C. HoOverview
Study Start/End
Jun 18, 2018 to May 22, 2019Locations
Vancouver General HospitalPhone
604-875-5296Purpose of Study
The purpose of this study is to evaluate the efficacy and safety of two dosage strengths of a new drug (PF-04965842) relative to placebo over 20 weeks of study participation.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.